Global Generic Drugs Market to Reach US$ 628.0 Billion by 2032, Bolstered by Increasing Prevalence of Chronic Diseases

April 05, 2023 | Healthcare

According to the latest report by IMARC Group, titled "Generic Drugs Market Report by Therapy Area (Central Nervous System, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology, and Others), Drug Delivery (Oral, Injectables, Dermal/Topical, Inhalers), Distribution Channel (Retail Pharmacies, Hospital Pharmacies), and Country 2024-2032," the global generic drugs market size reached US$ 367.1 Billion in 2023. Generic drugs are medications equivalent to brand name drugs with the same active ingredients, dosage form, strength, route of administration, quality, and intended use. They offer precise results and high accuracy, and clinical benefits at an affordable price, and the production does not require extensive research as compared to brand-name drugs. Their production does not involve the repetition of clinical and animal studies to measure the effectiveness and safety of the medicine. 


Global Generic Drugs Market Trends:

The surging prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, and the increasing healthcare expenditure represent one of the major factors driving the demand for generic drugs around the world. Furthermore, the rising aging population, which is more prone to such ailments, is fueling the growth of the market. Moreover, several initiatives undertaken by governing agencies of numerous countries to promote the usage of generic drugs are favoring the growth of the market. They are also undertaking measures to reduce healthcare costs and offering quality healthcare facilities that are accessible to all. In addition, the growing awareness about the benefits of using generic drugs is influencing the market positively. Apart from this, the increasing number of smokers and alcohol consumers on account of sedentary lifestyles, hectic work schedules, and changing dietary patterns is resulting in a rising number of cancer patients worldwide, which in turn, is catalyzing the demand for generic drugs. Besides this, the growing number of online pharmacies, which is making it more convenient for patients to access generic drugs, is creating a positive outlook for the market. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 628.0 Billion by 2032, exhibiting a CAGR of 5.96% during 2024-2032.


Market Summary:

  • On the basis of the therapy area, the market has been segmented into the central nervous system, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, oncology, and others. Presently, central nervous system holds the largest market share.
  • Based on the drug delivery, the market has been classified into oral, injectables, dermal/topical, and inhalers. Oral currently accounted for the biggest market share.
  • On the basis of the distribution channel, the market has been bifurcated into retail and hospital pharmacies. At present, retail pharmacies hold the largest market share.
  • Region wise, the market has been divided into the United States, China, Brazil, Germany, France, India, United Kingdom, Japan, Canada, Italy, and others. Amongst these, the United States enjoys the leading position in the market.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players include Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited, and Aspen Pharmacare Holdings Limited.


Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Therapy Area, Drug Delivery, Distribution Channel, Country
Countries Covered United States, China, Brazil, Germany, France, India, United Kingdom, Japan, Canada, Italy, Others
Companies Covered Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited and Aspen Pharmacare Holdings Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. 


Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Generic Drugs Market to Reach US$ 628.0 Billion by 2032, Bolstered by Increasing Prevalence of Chronic Diseases
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More